electroCore to Participate at Canaccord Genuity MedTech & Diagnostics Forum
11 Novembro 2021 - 10:00AM
electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a
commercial-stage bioelectronic medicine company, today announced
that its management team will be available for virtual one-on-one
meetings at the Canaccord Genuity MedTech & Diagnostics Forum.
The conference is taking place virtually November 18, 2021. Details
are as follows:
Canaccord Genuity MedTech & Diagnostics
Forum:Date: Thursday, November 18, 2021Event: One-on-one
meetingsPlease contact your Canaccord Genuity representative if
interested in arranging a one-on-one meeting with electroCore
management during the event.About electroCore,
Inc.electroCore, Inc. is a commercial stage bioelectronic
medicine company dedicated to improving patient outcomes through
its non-invasive vagus nerve stimulation therapy platform,
initially focused on the treatment of multiple conditions in
neurology. The company's current indications are the preventive
treatment of cluster headache and migraine, the acute treatment of
migraine and episodic cluster headache, the acute and preventive
treatment of migraines in adolescents, and paroxysmal hemicrania
and hemicrania continua in adults.
For more information, visit www.electrocore.com.
Investors:
Rich Cockrell
CG Capital
404-736-3838
ecor@cg.capital
or
Media Contact:
Jackie Dorsky
electroCore
908-313-6331
Jackie.dorsky@electrocore.com
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024